G. Hughes

发表

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study

J. Schopohl, J. Bollerslev, A. Arafat, 2014, Journal of clinical pharmacology.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study

E. Wolin, V. Giannone, K. Hu, 2013, Cancer Chemotherapy and Pharmacology.

Pasireotide ( SOM 230 ) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR : results from a phase II study

L. Kvols, B. Wiedenmann, R. Arnold, 2012 .

patients with advanced neuroendocrine tumors refractory or resistant to

L. Kvols, B. Wiedenmann, R. Arnold, 2012 .

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

L. Kvols, B. Wiedenmann, R. Arnold, 2012, Endocrine-related cancer.

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

L. Chow, A. Bardia, N. Harbeck, 2019, The New England journal of medicine.

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly

S. Melmed, J. Schopohl, P. Caron, 2018 .

Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7.

L. Chow, A. Bardia, N. Harbeck, 2015 .

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study

J. Bertherat, M. Fleseriu, J. Schopohl, 2013, Pituitary.

Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial

J. Bertherat, L. V. Van Gaal, J. Schopohl, 2014, Pituitary.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

L. Chow, A. Bardia, N. Harbeck, 2018, The Lancet. Oncology.

Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results.

L. Chow, A. Bardia, N. Harbeck, 2019, Journal of Clinical Oncology.

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

J. Schopohl, J. Newell-Price, A. Lacroix, 2014, Clinical endocrinology.

Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

A. Bardia, N. Harbeck, D. Tripathy, 2018 .

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

S. Melmed, J. Schopohl, P. Caron, 2013, Pituitary.

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

S. Melmed, J. Schopohl, P. Caron, 2013, Pituitary.

Long-term pasireotide use leads to improvements in the biochemical parameters of Cushing's disease: 24-month results from a randomized phase III study

J. Bertherat, J. Schopohl, W. Ludlam, 2012 .

Long-term use of pasireotide in Cushing's disease: 24-month safety results from a randomized phase III study

J. Bertherat, J. Schopohl, W. Ludlam, 2012 .

NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

P. Fasching, G. Hortobagyi, S. Verma, 2019, Journal of Clinical Oncology.

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

J. Schopohl, J. Newell-Price, A. Lacroix, 2014, Clinical endocrinology.